Teva Pharmaceutical Industries Ltd. ADR-1.25% $19.09B ...

mapping gene expression to particular locations in the brain to try to identify and validate new drug targets for the neurodegenerative disorder. GSK is paying out €33.5 million in cash to get ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

After hours: February 7 at 6:55:00 PM EST Loading Chart for GSK ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and ...